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Abstract Pancreatic islet transplantation is a therapeutic
option to replace destroyed β cells in autoimmune diabetes.
Islets are transplanted into the liver via the portal vein;
however, inflammation, the required immunosuppression,
and lack of vasculature decrease early islet viability and
function. Therefore, the use of accessory therapy and
biomaterials to protect islets and improve islet function
has definite therapeutic potential. Here we review the
application of niche accessory cells and factors, as well as
the use of biomaterials as carriers or capsules, for
pancreatic islet transplantation.
Keywords Type 1 diabetes.Islet transplantation.Islet
niche.Biomaterial.Encapsulation
Introduction
Type 1 diabetes (T1D) is caused by the autoimmune
destruction of pancreatic β cells. Treatment is optimized
insulin injections with regular monitoring of blood glucose
concentration. Although insulin therapy has improved
quality of life for patients, many patients suffer from
hypoglycemic episodes [1], have suboptimal glycemic
control which increases the risk of long-term diabetes
complications [2], and prevalence of coma, seizure, or
death [1]. Thus, replacement of islet β-cell mass is an
attractive option for patients not only to avoid insulin
injection, but also to avoid complications associated with
T1D. Replacement of islet β cells can be performed either
by whole pancreas or pancreatic islet transplantation.
Pancreatic islet transplantation is technically much easier
for the patient, but has variable long-term success [1]. This
is largely due to the intravascular hepatic transplantation
site and resultant blood-mediated inflammatory reactions
[3], low oxygen tension [4], and immunosuppressive drugs
[5–8]. Thus, improvements that include encapsulation, co-
transplantation with accessory cells or factors with or
without a biomaterial, and alternative transplantation sites
have been suggested to improve islet function and survival,
potentially without the need for immunosuppression. We
will introduce the native islet niche, report the current status
of pancreatic islet co-transplantation with accessory cells/
factors, and the use of biomaterials as islet carriers or for
encapsulation. With respect to encapsulation, the reader is
also referred to other reviews [9–11].
Native β Cells and Their Surrounds
The five endocrine cell types that comprise the islets of
Langerhans work as a micro-organ to maintain glucose
homeostasis. The most important cell type for this function
is the insulin-producing β cell, which senses circulating
nutrient levels in the blood and responds by secreting
insulin [12].
β Cells rely on pancreatic and non-pancreatic environ-
ments for cues that promote their function and number [12].
Within islets, a dense vascular network exists, which is
essential for efficient insulin secretion and oxygen transfer.
β Cells interact with the endothelial cells of the capillary
network via the vascular basement membrane. Mouse β
cells secrete vascular endothelial growth factor (VEGF-A)
to promote vascular development, whereas the basement
membrane secreted by the endothelial cells supports insulin
gene expression and secretion and β-cell proliferation [13,
14]. Human islets contain a second basement membrane,
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contacts between β cells, facilitated by several transmem-
brane proteins, are important for optimal insulin expression,
content, and glucose-stimulated insulin secretion (GSIS)
[17, 18]. β and α cells appear to have reciprocal secretory
responses that cooperate to maintain glycemic stability [19].
Because of the β to α cell blood flow, the relationship
between insulin and glucagon secretion is hypothesized to
be determined by β-cell paracrine effects on α cells.
However, β cells express glucagon receptors and these are
involved in the glucose competence of β-cell insulin
secretion [20]. The tight relationships between the major
endocrine islet cells are supported by the tri-laminar
architecture of human islets whereby one layer of β cells
appears to be sandwiched between two α cell–enriched
layers [21]. Islets are also innervated with neurons from
parasympathetic and sympathetic nervous systems. Inter-
actions between parasympathetic neurons and β cells
activate specific receptors to promote GSIS. The opposite
occurs from sympathetic neuronal input to inhibit insulin
secretion [22].
In addition to interactions within the islet, the β cell also
receives important signals from non-pancreatic tissues.
β Cells are reported to interact with the liver, bone, fat,
and gut [12]. Perhaps the best known example is the
communication that occurs between the endocrine cells of
the intestine and the β cells. By binding to specific
G-protein-coupled receptors on the β cell, incretins, which
are secreted by the enteroendocrine cells, stimulate insulin
secretion [23].
Islet transplantation requires isolation of the islets from
the remainder of the pancreas. This process involves
enzymatic digestion of the pancreas and purification of
the islets via density centrifugation [1], and destroys the
vasculature and nerve distribution within islets. Moreover,
connections to the rest of the pancreas and potentially
outside the pancreas are also lost [24]. To recreate this
β-cell niche shortly after transplantation is likely to be
beneficial for β-cell function and survival.
Islets and Growth Factors/Proteins
V ascular Endothelial Growth Factor (VEGF-A)
Newly transplanted islets require the process of angiogen-
esis to establish adequate blood supply for survival post
transplantation. This process occurs over a 2- to 4-week
period in small [25, 26] and large animal [27] models, and
is aided by the endothelial cell mitogen, VEGF-A. β Cells
secrete VEGF-A under normal conditions [13, 14, 28] and
it has been shown in vitro that hypoxic conditions increase
VEGF-A protein expression, which may act as the initiator
of re-vascularization after transplantation [28]. It appears
that β-cell production of VEGF-A is required for the
formation of new vessels and a competent islet vasculature,
because in animal models it is shown that increased blood
flow and normoglycemia is achieved by VEGF-A transgene
expression in transplanted islets, but not with exogenous
VEGF-A treatment [29]. The importance of β-cell VEGF-A
secretion was confirmed in a knockout VEGF-A mouse
model in which VEGF-A–deficient islets had markedly
reduced vascular density 1 month after they were trans-
planted into a nondiabetic (NOD)–severe combined immu-
nodeficiency mouse [30].
Extracellular Matrix Proteins
The basement membrane contains several extracellular
matrix proteins such as laminins and collagens that provide
support for β-cell function via β1 integrin receptors [13–
15]. The importance of extracellular membrane proteins
was demonstrated by the observation that a laminin 5–rich
matrix allows β-cell spreading via α6β1 integrins [31] with
decreased apoptosis [32], enhanced expression of cell cycle
proteins [33], and improved insulin secretion of rat β cells
[31, 33].
Islets and Accessory Cells
Endothelial Cells
Although β-cell signals are important for the vascular
network and proper islet function, the source of endo-
thelial cells can vary. Experimentally, it is shown that
endothelial cells can be derived from progenitors in the
bone marrow. Several studies have shown that endothe-
lial reporter gene–positive cells are located within islets
after transplantation of bone marrow from mice with
endothelial reporter transgenes [34, 35]. It is further
shown that islet graft vasculogenesis from bone marrow
precursors is superior to tissue-derived vasculogenesis and
results in better islet function post transplant [36]. The
benefits of endothelial cell or endothelial precursor cells to
transplanted islets have been investigated in diverse
settings. Johansson et al. [37] combined the revasculari-
zation properties of endothelial cells and their ability to act
as a barrier and created a human endothelial cell coating
on human islets prior to transplantation in an effort to
protect islets from instant blood-mediated inflammatory
reactions (IBMIRs). When transplanted into mice, these
composite grafts provoked less activation of coagulation
and complement and less infiltrating immune cells than
non-coated islets, providing proof of concept for such a
strategy [37].
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Bone marrow cell transplantation is suggested as a therapy
to improve islet function. In addition to possible immune
protection, direct benefits to the islets have been shown. A
study by Ianus et al. [38] observed that transplantation of
male bone marrow cells expressing green fluorescent
protein (GFP) into lethally irradiated female recipient mice
resulted in positivity for Y chromosome and GFP in 1.7%
to 3% of pancreatic islet cells. These cells also expressed
certain β-cell genes and transcription factors, and the
authors concluded that bone marrow stem cells can
differentiate into β cells. Hess et al. [39]n o t e das i m i l a r
frequency of insulin-positive GFP-positive cells but did
not ascribe this to direct differentiation. Other reports
could not confirm differentiation of bone marrow cells into
β cells in pancreatic injury and transplant models [40]. In
these studies, migration to the pancreas was observed in
addition to the amelioration of hyperglycemia and a partial
or significant increase in β-cell mass, but no transdiffer-
entiation of cells into β cells was seen [40]. Collectively,
these studies indicate that bone marrow cells do not
differentiate into β cells, but indirectly support β-cell
function by either adopting a hematopoietic or endothelial
cell fate or evoking the proliferation of recipient endothe-
lial cells [40].
Mesenchymal Stromal Cells
One subset of progenitor cell that can be isolated from bone
marrow are multipotent mesenchymal stromal cells
(MSCs). These are a heterogenous population that can
differentiate into cell types of the mesoderm embryonic
lineage (osteoblasts, chondrocytes, and adipocytes), and
experimentally have been shown to have wider differenti-
ation capacity. In vitro they adhere and proliferate on tissue
culture plastic in colonies and maintain a fibroblast-like
morphology. The interaction between MSCs and islets was
demonstrated by Sordi et al. [41], who showed in a bone
marrow transplantation model that GFP-positive bone
marrow cells migrated to islets and, once isolated, demon-
strated an MSC phenotype and the ability to differentiate
into osteoblasts. Following this, studies using induced
diabetes mouse models confirmed that MSC-islet co-
transplantation not only reversed diabetes but also signif-
icantly increased the number of recipient islets [42, 43].
Similarly, co-infusion of MSCs with a small number of
islets allowed the return of normoglycemia and, moreover,
an increase in capillary density was noted in these grafts
compared with islets alone [44]. Other in vitro studies show
that islets co-cultured with MSCs have higher levels of anti-
apoptotic signaling molecules [45] and hypoxia-resistant
molecules under hypoxic conditions [46].
MSCs also have immunoregulatory activities. With
respect to islet transplantation, it was shown that a murine
stromal cell line was able to prevent graft rejection in a
major histocompatibility complex–mismatched islet trans-
plantation model [47]. Matrix metalloproteinases (MMPs),
specifically MMP-2 and −9, were speculated to mediate the
protective effects seen after in vivo administration of MSCs
with allogenic islets [48]. Furthermore, it was found that
MSCs were capable of reducing islet infiltration and
maintaining interleukin-10–secreting regulatory (FOXP3
+)
Tcells in an autoimmune diabetes model [49]. These results
were extended to a non-human primate model in which
allo-MSC infusion–increased peripheral T-regulatory cells
coincided with stable islet allograft function [50].
In view of the numerous avenues to protect islet cell
grafts and improve their function, it follows that strategies
to implement and optimize the addition of growth factors,
proteins, and accessory cells to islets should be considered.
Also, carriers to co-localize islets and their support factors
should be explored.
Improving an Islet’s Home
Comfort and Guidance
The housing of islets within a biomaterial at alternate
transplantation sites is a potential therapeutic option.
Material for such a therapy can be biologically derived or
synthetically made. In the past few years there has been a
propensity to focus on the glycosaminoglycan, heparin, and
synthetic biodegradable materials as carriers for islet
endocrine cells.
Heparin
Heparin is a complex polymer that interacts with numerous
enzymes and proteins in the body. Heparin is commonly
used as an anticoagulant, but also contains binding sites for
several growth factors and chemokines [51]. Heparin
binding has previously been used to improve the biocom-
patibility of biomaterials for transplantation. Under this
concept, Johansson et al. [37] directly heparinized the
surface of islets to render them blood biocompatible. By
immobilizing heparin to islets, they reasoned that this could
inhibit coagulation and complement activation thereby
reducing IBMIRs and intraportal islet loss. Using a biotin
and avidin coating approach, they were able to transplant
heparinized islets into a diabetic mouse and pig model.
Blood glucose of mice transplanted with heparinized islets
was normalized 10 days post-transplantation and a decrease
in intraluminal clotting was observed in pigs transplanted
with heparinized islets compared with untreated islets [52].
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to heparinized islets without affecting insulin secretion and
that in vitro the VEGF-A acted as an endothelial cell
attractant [53••].
Self-assembling amphiphile peptides bound to heparin
[54] have also been used as a growth factor delivery system
for islet transplantation [55]. Using a diabetic mouse model,
islets were transplanted into the omentum pouch alone,
with local administration of VEGF-A and basic fibroblast
growth factor (FGF) or together with heparin-coated poly
(L-lactic acid/lactide) (PLA) matrices with or without
VEGF-A and FGF. A higher proportion of mice trans-
planted with biofunctionalized heparin-PLA scaffolds
achieved normoglycemia and an increase in vessel density
at the transplantation site, when compared to islets with or
without administration of growth factors or heparin-PLA
scaffolds [55]. Furthermore, this group recently showed that
the biofunctionalized heparin-binding peptides could attach
to isolated murine islets and increase islet viability, insulin
secretion, and endothelial cell sprouting from within the
islet [56]. These encouraging results with heparin suggest
that synthetic materials with the ability to incorporate
heparin and mimic the natural environment without elicit-
ing an immune response (e.g., poly(ethylene glycol) [PEG]
hydrogels) may improve islet transplantation outcome [57].
A variety of synthetic biomaterials has been used for islet
culture and transplantation (Table 1) and is discussed below.
Lactic Acid–Based Polymers
Based on the small organic molecule, lactic acid polymers
(PLA) can be easily manipulated during production or post-
polymerization to produce a material with varying proper-
ties [58]. We have already discussed its use in combination
with heparin-binding nanostructures. One copolymer that
has been used in animal models of islet transplantation
derives from a mixture of lactide and glycolide, poly(lactic-
co-glycolic acid) (PLGA). One notable feature of PLGA is
the ability to decrease degradation time by increasing the
ratio of glycolide to lactide [58].
The use of these polymers with islets was published in
2005. PLGA scaffolds with a ratio of 90% glycolide to 10%
lactide (Vicryl®; Ethicon Inc., Somerville, NJ) were coated
with varying numbers of islets in a matrigel suspension and
transplanted into the epididymal fat pad of diabetic mice.
More mice were able to achieve normoglycemia when
transplanted with the islet-matrigel–coated scaffold when
compared with free islets or islets in matrigel suspension,
and insulin content in transplanted islet-matrigel–coated
scaffolds was similar to that of islets transplanted under the
kidney capsule [59]. Modifications to this approach have
included PLGA scaffolds with interconnected pores from
250 to 400 μm so as to house a marginal islet mass for
transplantation. Mice receiving such grafts into the folds of
intraperitoneal fat achieved normoglycemia at a faster rate
than mice receiving islets alone in the same location [60].
Another study used the commercially available Ethisorb®
(Codman, Raynham, MA), comprised of Vicryl® with a
poly-p-dioxanone (PDS) backing, to determine islet graft
survival into the omentum pouch of pancreatectomized
dogs. Four animals received autologous islets seeded into
the polymer scaffold and two received free islets into the
omentum pouch. All four animals transplanted with the
scaffold and none of the control animals achieved normo-
glycemia without the administration of exogenous insulin
secretion for a maximum of 5 months [61•].
Other Polyesters
Polyhydroxyalkanoates (PHA) are polyesters produced by
microorganisms in unfavorable growth conditions and have
been commonly used in many medical devices. Copolymers
of 3-hydroxybutyrate and 3-hydroxyhexanoate (PHBHHx)
were used in a pilot study to determine the effect of PHBHHx
on cluster formation and insulin secretion of the murine islet
β-cell line NIT-1. After overnight culture, cell clustering and
later islet-like aggregates were seen in wells containing
PHBHHx. Cells cultured on PHBHHx had increased insulin
secretion and viability compared to islets with tissue culture
alone, PLA, and another PHA copolymer derivative [62].
Hydrogels
Hydrogels, as the name implies, consist of highly absorbent
polymers. By varying the amount of crosslinking of
synthetic hydrogels, mechanical properties of the hydrogels
can be attuned. A class of covalently linked hydrogel is
based on the synthetic polymer PEG. The characteristics of
PEG hydrogels include low immunogenicity, protein
absorption, and cell adhesion. In a cell transplantation
setting, these bio-inert properties can be modified by
binding growth factors and incorporating cell attachment
and enzyme-sensitive peptide sequences to allow the cells
of interest to attach, proliferate, and function [63]. Further-
more, copolymers of PEG can be formed to create an
amphiphilic polymer that has both hydrophobic and
hydrophilic properties. Ito and Taguchi [64] used such a
modification by incorporating oleyl hydrophobic tails to
crosslink rat insulinoma cells to form spheroids and found
that oleyl-O-PEG crosslinked cells were more glucose
responsive than non-crosslinked cells.
Another synthetic polymer with similar properties to that
of PEG hydrogels is the poly(vinyl alcohol) (PV A) hydro-
gel. In a recent report, PV A was modified with thiol-alkyl
side chains to allow attachment to the lipid bilayer of
endocrine islet cells and further conjugation of protein-
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nolytic activity. Treated islets were able to secrete insulin
comparable with untreated and PV A-alkyl islets in vitro and
showed increased fibrinolysis, suggesting that they could
potentially dampen IBMIRs [65].
Unlike the above hydrogels, poly(N-isopropylacryla-
mide) (NIPA) polymer gels are thermo-responsive, under-
going a volume change at about 34°C. A tissue engineering
approach was performed by Shimizu et al. [66], in which
isolated rat islets were trypsinized to form single cell
suspensions and seeded onto NIPA hydrogels. V arious
extracellular matrix coatings were used to enhance attach-
ment in vitro, with laminin 5 favoring viability and insulin
secretion by single β cells. After 48 h of culture, the islet
cell sheets were placed at 20°C to allow removal and were
transferred to a support membrane for syngeneic transplan-
tation. Weak insulin and glucagon staining were observed
7 days post-transplantation [66]. Although further function-
al data were not shown, this report acts as a proof of
concept that thermo-reactive NIPA polymers could poten-
tially be used as an alternate delivery system for islet
transplantation.
Biopolymer Films
To determine the best substrate for islet survival and
function, a high-throughput approach was taken by Wil-
liams et al. [67] and Mei et al. [68•]. In Williams et al.’s
group [67], films from different materials were cast or
coated as a monolayer on tissue culture plastic and seeded
Table 1 Synopsis of reports of pancreatic islet cells with biomaterial carriers
Biomaterial type In vitro outcome In vivo outcome Reference
Heparin Attachment via biotin-avidin
interaction
Normalized blood glucose in
diabetic mice. Decreased
intraluminal clotting in pigs
Cabric et al. [52]
Heparin + VEGF-A Normal insulin secretion maintained.
Attracted endothelial cells
– Cabric et al. [53••]
Heparin-PLA +
VEGF-A + FGF
– Normalized blood glucose levels in
mice. Increase in blood vessel
density
Stendahl et al. [55]
Heparin-PLA +
VEGF-A + FGF
Attachment on islets. Increased islet
viability and insulin secretion.
Initiated islet endothelial cell
sprouting
– Chow et al. [56]
PLGA-matrigel – Normalized blood glucose levels in
diabetic mice with comparable
insulin secretion to islets under the
kidney capsule
Dufour et al. [59]
PLGA – Normalized blood glucose levels in
mice. Comparable results to islets
under the kidney capsule
Blomeier et al. [60]
Ethisorb® (PLGA + PDS) – Normalized pancreatectomized
canine blood glucose for 2 (50%)
and 5 (25%) months without
exogenous insulin administration
Kin et al. [61•]
PHBHHx Cell clustering and islet-like aggre-
gates of NIT-1 cells within 72 h
with an increase in insulin secre-
tion and viability
– Yang et al. [62]
Oleyl-O-PEG Crosslinked RIN cells into
spheroids, insulin secretion was
increased
– Ito and Taguchi [64]
PV A-alkyl + urokinase Attachment on islets with
fibrinolytic activity and
comparable insulin secretion
– Totani et al. [65]
NIPA + laminin 5 Single rat islet cells cultured as a
sheet remained viable and glucose
responsive
Insulin and glucagon
immunostaining were present
7 days post-transplantation
Shimizu et al. [66]
Ethisorb® (Codman, Raynham, MA)
FGF fibroblast growth factor; NIP A poly(N-isopropylacrylamide); PDS poly-p-dioxanone; PEG poly(ethylene glycol); PHBHHx
3-hydroxybutyrate and 3-hydroxyhexanoate; PLA poly(L-lactic acid/lactide); PLGA poly(lactic-co-glycolic acid); PVA poly(vinyl alcohol);
VEGF-Avascular endothelial growth factor
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graded by the number of attached islet clusters. Laminin
coatings and mildly hydrophobic polymers (e.g., low
molecular weight PLGA) performed well, in addition to
double layer coatings, which were comprised of PLGA on
the bottom with a second material (carboxyl groups,
methylesters) on top. Islet cell morphology appeared spread
and ruffled and when cells were added in multiple layers,
cells of all layers remained viable for 7 days [67]. The
group of Mei et al. [68•] analyzed a microarrayed library of
496 different polymers, comprised of 22 different acrylate
monomers in different combinations. Monomers were
chosen with a range of chemical groups, crosslinking
density and varying hydrophobicity and hydrophilicity to
generate chemically diverse polymers. Attachment of islet
cells was supported by few polymers with distinct
characteristics. The findings were confirmed in another set
of polymers [68•]. Further studies are required to determine
whether the dispersed attached β cells are still glucose
responsive in vitro and whether polymers as a transplanta-
tion unit for islets could improve glycemia in diabetic
animal models.
Protection and Security
A major drawback of islet transplantation is the immuno-
suppression that is required to prevent transplant rejection.
Not only does this cause undesired side effects to the
immune system, the immunosuppressive drugs also have
detrimental effects on islet function and survival [5–8].
Since the late 1970s, researchers have pursued encapsulat-
ing both allo- and xeno-derived islets via different methods,
as a means of protecting the islets and potentially
eliminating the need for immunosuppression [9]. The
concept of encapsulation involves separating the trans-
planted cells from the host immune system by a semiper-
meable, biocompatible membrane. The membrane should
contain pores small enough to prevent entry of inflamma-
tory cells and large proteins, such as antibodies, but large
enough to allow transfer of nutrients, oxygen, and
hormones [10]. To date, three types of encapsulation
systems have been studied by researchers in the field.
Extravascular Chambers
Pioneering islet transplantation animal studies using planar
or tubular diffusion chambers in the early 1980s produced
variable results due to varying hormone diffusion capabil-
ities of the membranes used and overgrowth of fibroblasts
in the graft and/or chamber. The main advantage of these
devices was the ease of graft chamber retrieval from the
various extravascular transplantation sites. However, the
drawback was the decrease in islet function due to fibrosis,
lack of immediate vascularization, and extended nutrient/
hormone diffusion time, brought about by the design of
these chambers [69]. The use of smooth polyacrylonitrile-
polyvinyl chloride (PAN-PVC) membranes in the 1990s
markedly decreased the adhesion and fibrosis seen in these
earlier studies [9]. In an isolated clinical study, as a proof of
concept, patients with diabetes were transplanted with a
marginal mass of allogenic islets in chambers at a
subcutaneoussitewithoutimmunosuppression.Thechambers
were biocompatible and after 2 weeks, grafts were removed
and islets were still glucose responsive [70].
Research since this time has concentrated on optimizing
chamber designs [71, 72], improving vascularization; either
by treating with growth factors pretransplantation [73]o ra t
the time of transplantation [74, 75] or implanting the device
prior to islet insertion [76] or improving oxygen transfer
[77••]. For example, a recent study showed islet function
retention of allogeneic pig islets contained within a
subcutaneous transplanted, oxygen-refueled macrochamber
(βAir device). This device was comprised of a chamber that
provided oxygen supply through a gas-permeable membrane
to the alginate immobilized islets, which were immunopro-
tected by a Teflon membrane (against cellular invaders) and a
mannuronic acid-alginate–coated Teflon membrane (against
antibody and complement penetration). They showed the
device was biocompatible after 13 days with no local
inflammatory or fibrotic reactions and that the islets main-
tained similar insulin secretion levels when compared with
levels prior to transplantation [77••].
Progress is still required for the successful translation of
extravascular grafts to the clinic; specifically, accurate
chamber design to reduce membrane stress and breakage
[9], improvement of the graft vascularization, and a
transplantation site that is minimally evasive to allow for
removal to replace exhausted islets, if required [9, 10].
Intravascular Chambers
Around the time of extravascular device transplantation, the
notion of connecting small chambers to the host vascular
system and separating islets with an immunoprotective
membrane received attention [9]. These intravascular
devices overcame the diffusion oxygenation and nutrition
limitations due to a closer proximity to the blood [69]. The
first reports to use such a system achieved normoglycemia
in autologous diabetic rat [78, 79] and monkey models [79].
Further studies by these groups [80–82] and others [69]
improved chamber design to decrease coagulation and
demonstrated functional allogeneic [80, 81] and xenogeneic
[69, 82] islet grafts, without the use of immunosuppression.
However, exogenous insulin was still required [82]. A
modified approach was taken by Cronin et al. [83]i na
diabetic mouse model, which involved running a portion of
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was filled with a Matrigel® (BD Biosciences, Franklin Lakes,
NJ) solution supplemented with FGF and heparin [84]o r
Gelita-Spon® (Gelita Medical BV ,A m s t e r d a m ,N e t h e r l a n d s )
supplemented with nerve growth factor (NGF) [85]. In the
matrigel study, islets were seeded at the time of implantation
or 3 weeks after prevascularization of the chamber. Only the
islets in the prevascularized chamber could improve glyce-
mia of the mice [84]. Interestingly, the later study demon-
strated that prevascularization of the chamber was not
required when syngeneic islets were seeded with NGF. In
this condition, 80% of mice achieved normoglycemia
compared with 0% of mice receiving islets on the gelatin
sponge alone [85]. This system takes advantage of an easily
vascularized transplantation site, which allows optimal
diffusion while eliminating protein deposition and coagula-
tion around the graft.
Microencapsulation
Microencapsulation allows single or groups of islets to be
immunoisolated from the host system via spherical drop-
lets/beads or multilayering systems. This form of encapsu-
lation has been the most intensely studied over the past
three decades due to ease of production, mechanical
stability, large surface-to-volume ratio, and optimal
diffusion capability [10]. The size of the microspheres in
early studies ranged from 600 to 800 μm; however, recent
fabrication techniques have allowed 350- to 500-μm
microspheres to be produced [86]. Hydrogels including
alginate, poly(hydroxyethyl methacrylate-methyl methac-
rylate), agarose, acrylonitrile copolymers, chitosan, and
PEG are the most frequently used materials for microen-
capsulation [10]. To date, the most preferred biomaterial
for microencapsulation is based on alginate. Alginate
consists of linear copolymers comprised of β-D-mannur-
onic and α-L-guluronic acids. It is the various combina-
tions of these polymers that solidify around the islet(s) in a
divalent cationic solution. V arious coatings (e.g., poly-L-
lysine) to improve mechanical stability and improve bio-
compatibility of these microcapsules have also been exten-
sively studied [10].
Achievement of normoglycemia was seen in early
studies with alginate-based encapsulated allogeneic [9, 87]
and xenogenic [88, 89] islets transplanted into diabetic
rodent models. However, attempts to upscale this system to
larger animal models were inconsistently successful [90].
Soon-Shiong et al. reported both in a diabetic dog [91] and
one T1D patient [92] that insulin independence could be
achieved for up to 5.5 and 9 months, respectively, by
transplantation of encapsulated allogeneic islets and treat-
ment with cyclosporine. However, others reported an
Fig. 1 Biomaterial carrier
for islet transplantation. An
optimal biomaterial for human
islet transplantation would be
one with large pore sizes to
accommodate islets, as well as
providing the possibility to be
biofunctionalized with growth
factors and potentially immuno-
suppressive drugs, and with
adhesion molecules so that
accessory cells can be localized
and with enzyme degradation
sites for eventual degradation,
allowing a functional revascu-
larized islet micro-organ to
remain at the transplantation
site. (Adapted from Lutolf
and Hubbell [98].)
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diabetic dogs transplanted with auto-, allo-, or xenogeneic-
encapsulated islets. The later studies did not use immuno-
suppression but the authors speculated that the decrease in
transplanted islet-to-surface ratio and fibrotic overgrowth
affected the efficiency of these grafts [90].
Whether immunosuppression is required to prolong
microencapsulated islets is debated. In an ideal situation,
encapsulated allogeneic or xenogenic islets would have
long-term survival with minimal immune response and no
requirement for immunosuppression. However, the micro-
capsule fabrication and composition have fallen short of
this expectation [93]. Recent reports are now attempting to
combine microcapsule optimization with immunosuppres-
sion to determine whether graft function can be extended.
For example, Safley et al. [94, 95] observed that inhibition
of T-cell costimulatory molecules CD28/B7 by CTLA-Ig in
NOD mice transplanted with microencapsulated porcine
islets extended graft function compared with no treatment.
Similar results were also seen elsewhere [96]. Safley et al.
[94, 95] showed that empty microcapsules did not elicit an
immune response and it was the presence of the xenogenic
islets that attracted large numbers of leukocytes to the
transplantation site. Others showed that the composition of
the microcapsules also affects the biocompatibility of the
microcapsule [93]. In this report, cyclosporin A treatment
of rats transplanted with low or high guluronic acid alginate
bovine-encapsulated islets increased the longevity of the
graft by at least twofold. Cyclosporin A decreased the
amount of fibrotic overgrowth on the low guluronic
alginate, with similar results in empty microcapsules [93].
Much of the experimental work with alginate microcapsules
has used nonstandardized and varying alginate composi-
tions with varying results [10]. Clinical application,
conversely, requires clinical-grade alginate and rigorous
evaluation of the product [97].
Conclusions
Pancreatic islet transplantation has come a long way in
almost 40 years, but is still generally considered an
experimental procedure. Advances in the fields of material
science, nanotechnology, immunology, and islet transplan-
tation have been able to shed some light on how we might
be able to improve long-term survival and function of
pancreatic islet transplants. What’s next? We think it would
be beneficial to use the knowledge of β-cell interactions
within its native environment and recreate this islet niche as
best as possible in a carrier or capsule (Fig. 1). We envision
creating a “microenvironment” for human islets that would
include not only the islets, but accessory cells, proteins, and
possibly local immunosuppression housed within a bio-
compatible material. The material would support islets for
the time required for the body to recreate a supportive
microenvironment around the transplantation site and
eventually be degraded so that a suitable islet micro-organ
would remain. These activities provide the alternative for
human islets and must be complemented by efforts in
encapsulation so that other sources of β cells (e.g.,
xenogeneic islets and stem cell–derived β cells) can also
find their way to clinical therapy.
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